Phase2a Primaquine Dose Escalation Study

Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low single-dose primaquine for gametocidal activity against P.falciparum among adult glucose-6-phosphate dehydrogenase (G6PD)-normal malaria patients.

Inclusion Criteria:

• Male
• Age >= 18 years and < 50 years
• Malaria blood thick film positive
• Presence of gametocytes on thick blood film
• Agrees to admission to study ward for 26 hours post diagnosis and available for follow up visits
• No allergies to study drugs
• Hemoglobin >= 8 g/dl
• No evidence of severe or chronic disease
• Written, informed consent